Impact of Depression on Work Productivity and Its Improvement after Outpatient Treatment with Antidepressants

Woo, Jong Min; Kim, Won; Hwang, Tae Yeon; Frick, Kevin D.; Choi, Byong Hwi; Seo, Yong Jin; Kang, Eun-Jin; Kim, Se Joo; Ham, Byung Joo; Lee, Jung Hoon; Park, Yu Lee

doi:10.1016/j.jval.2010.11.006

Cited by 98 publications

(79 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wang et al [2011] estimated that 83% workers with mental disorders needed treatment but that only 31% had received work place accommodations. Studies have shown that employers would benefit in productivity and cost savings with enhanced depression care consisting of a depression screen and care management for workers with depressive illnesses [Wang et al, , 2008Woo et al, 2011]. The stigma attached to having a psychiatric disorder is such that employees may be reluctant to seek treatment, especially fearing that they might jeopardize their jobs in doing so.…”

Section: Study Limitationsmentioning

confidence: 99%

Occupation and the prevalence of current depression and frequent mental distress, WA BRFSS 2006 and 2008

Fan

Bonauto

Foley

et al. 2012

American J Industrial Med

View full text Add to dashboard Cite

show abstract

Section: Study Limitationsmentioning

confidence: 99%

Occupation and the prevalence of current depression and frequent mental distress, WA BRFSS 2006 and 2008

Fan

Bonauto

Foley

et al. 2012

American J Industrial Med

View full text Add to dashboard Cite

show abstract

“…According to the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV), the main symptoms that define the diagnostic criteria for MDD are low mood, anhedonia and anergia, lasting for a period of at least two weeks [4]. The presence of these symptoms severely impairs daily functionality and contributes to loss of productivity [5,6]. MDD is associated with a variable prognosis and chronic course; the median duration of an episode is reported to be 23 weeks, with 25% of individuals proceeding to suffer further episodes in their lifetime [7].…”

Section: Introductionmentioning

confidence: 99%

The Role of Lipid Biomarkers in Major Depression

et al. 2017

View full text Add to dashboard Cite

In the UK, the lifetime-documented prevalence of major depressive disorder (MDD) is currently 10%. Despite its increasing prevalence and devastating impact on quality of life, the pathophysiological mechanisms underpinning MDD remain to be fully elucidated. Current theories of neurobiological components remain incomplete and protein-centric, rendering pharmacological treatment options suboptimal. In this review, we highlight the pivotal role of lipids in intra- and inter-neuronal functioning, emphasising the potential use of lipids as biomarkers for MDD. The latter has significant implications for improving our understanding of MDD at the cellular and circuit level. There is particular focus on cholesterol (high and low density lipoprotein), omega-3, and omega-6 polyunsaturated fatty acids due to established evidence in the literature of a link between atherosclerotic disease and major depression. We argue that there is significant potential scope for the use of such peripheral biomarkers in the diagnosis, stratification and treatment of MDD.

show abstract

“…1,2 Many studies have shown that people with MDD have increased absenteeism 3,4 and reduced work productivity 5 compared with the general population. Cognitive symptoms are common in MDD and have been shown to be present up to 94% of the time during depressive episodes and up to 44% of the time during periods of remission.…”

mentioning

confidence: 99%

Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder

McIntyre¹,

Florea²,

Tonnoir³

et al. 2016

J. Clin. Psychiatry

View full text Add to dashboard Cite

Objective: This post hoc analysis investigates the effect of vortioxetine on cognitive functioning and depressive symptoms in working adults with major depressive disorder (MDD).Methods: Population data from FOCUS, a double-blind, randomized, placebo-controlled study investigating the efficacy of vortioxetine versus placebo on cognitive functioning and depression in patients with MDD, were used to analyze mean change from baseline scores for the Digit Symbol Substitution Test (DSST), Trail Making Test A/B (TMT-A/B), Stroop, and Perceived Deficits Questionnaire (PDQ). FOCUS, conducted from December 2011 through May 2013, included adult patients with recurrent MDD according to DSM-IV-TR criteria. Change in depression severity (Montgomery-Asberg Depression Rating Scale [MADRS] total score) was analyzed using data from 3 additional short-term placebo-controlled studies (2 of which included duloxetine) and 1 relapse prevention study. Analyses were done according to patients' working status at baseline and workplace position. All analyses were made versus placebo. Results:In FOCUS, the effect versus placebo on the DSST was 5.6 for 10 mg and 5.0 for 20 mg (P < .001 for both doses) in working patients; the effect was 4.0 (P < .001 for both doses) in total study population. The effect remained significant when adjusting for change in MADRS. In patients with "professional" positions, the effect was 9.2 for 10 mg (P = .006) and 9.0 for 20 mg (P = .001). A similar pattern of results was also observed for TMT-A/B, Stroop, PDQ, and MADRS total score. The efficacy of duloxetine was not different in working patients (MADRS). Conclusions:The beneficial effects of vortioxetine on objective and subjective measures of cognitive functioning are greater in working patients with MDD; the observed benefits were independent of improvement in depressive symptoms. 6 Evidence indicates that among adults with MDD, cognitive symptoms account for more variability in workplace performance than does total depressive symptom severity. 7 These observations support research underscoring the notion that cognitive dysfunction is a critical mediator of role impairment in MDD. 8Results from 2 double-blind, randomized, placebo-controlled studies demonstrated a clinical benefit of vortioxetine on cognitive functioning in adults with MDD, including objective neuropsychological tests of executive functioning, speed of processing, verbal learning, and memory.9-11 These studies confirm and extend the results from an earlier double-blind, randomized, placebo-controlled, duloxetine-referenced study with vortioxetine in elderly (≥ 65 years) patients with MDD. 12The beneficial effect observed on measures of cognitive functioning with vortioxetine is of particular importance for individuals with MDD who are working and/or engaged in activities that place high demands on cognition (eg, educational pursuit). Because depression is primarily a disorder affecting people of working age, 13 it is important to understand how the effect of vortioxetine on cognit...

show abstract

Impact of Depression on Work Productivity and Its Improvement after Outpatient Treatment with Antidepressants

Cited by 98 publications

References 30 publications

Occupation and the prevalence of current depression and frequent mental distress, WA BRFSS 2006 and 2008

Occupation and the prevalence of current depression and frequent mental distress, WA BRFSS 2006 and 2008

The Role of Lipid Biomarkers in Major Depression

Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder

Contact Info

Product

Resources

About